English
French
German
Italian
Japanese
Portuguese
SpanishTrusted Resources: News & Meetings
Latest announcements and gatherings
Alnylam Presents New 18-Month Results From Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced new positive results from an 18-month analysis of exploratory cardiac endpoints in the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis. The 18-month findings show that in a pre-defined cardiac subpopulation, treatment with vutrisiran was associated with improvements in exploratory cardiac endpoints relative to external placebo, including levels of NT-proBNP, a measure of cardiac stress, and a trend towards improvement in echocardiographic parameters.
Consistent beneficial effects on cardiac measures were observed in the modified intent-to-treat (mITT) group. Additionally, in a planned cohort of patients from the mITT population, vutrisiran treatment reduced cardiac uptake of technetium on scintigraphy imaging relative to baseline in a majority of assessable patients, including those with Perugini grade >=2 at baseline, suggesting that patients with the highest degrees of cardiac amyloid burden may recognize benefit from a TTR silencer.
myBinderRelated Content
-
Steroids, IMiDs, and Alkylators in Amyoidosis: Dr. Larry Anderson – ASG Webinar 2/13https://www.youtube.com/watch?v=NrEjyVeJ...
-
Evolutive Echocardiographic Changes in Cardiac Amyloidosis: Look at the Whole PictureDoppler echocardiogram provides not only...
-
Keyur B. Shah, MDDr. Keyur Shah is a Chief of the Section...
-
Taxiarchis Kourelis, MDDr. Taxiarchis Kourelis is a hematology ...
-
Intellia CRISPR CAS9 Update – ASG Webinar 11/11https://www.youtube.com/watch?v=K2TmwAfu...
-
Localised Nasopharyngeal Amyloidosis: The Importance of Postoperative Follow-upLocalised nasopharyngeal amyloidosis is ...
-
Rafat Abonour, MDRafat Abonour is a Professor in the Depa...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Translation of this platform made possible through an independent education grant from
